ADT-OH
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


ADT-OH
Description :
ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases[1][5].Product Name Alternative :
5- (4-Hydroxyphenyl) -3H-1,2-dithiole-3-thione; ACS 1UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Apoptosis; FAKType :
Reference compoundRelated Pathways :
Apoptosis; Protein Tyrosine Kinase/RTKApplications :
Cancer-programmed cell deathField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/adt-oh.htmlConcentration :
10mMPurity :
98.55Solubility :
DMSO : 125 mg/mL (ultrasonic)Smiles :
S=C1SSC(C2=CC=C(O)C=C2)=C1Molecular Formula :
C9H6OS3Molecular Weight :
226.35Precautions :
H302, H315, H319, H335References & Citations :
[1]Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11 (1) :33.|[2]Yu S, et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission. Cell Death Dis. 2024 Jun 28;15 (6) :463. |[3]Xu H, et al. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer Med. 2023 Aug;12 (16) :17193-17211.|[4]Wei SW, et al. Role of the hydrogen sulfide-releasing donor ADT-OH in the regulation of mammal neural precursor cells. J Cell Physiol. 2022 Jul;237 (7) :2877-2887.|[5]Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedCAS Number :
[18274-81-2]

